Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Bi Enzyme Immobilization. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN115466756A discloses novel immobilized transaminases for sitagliptin production. Achieve high conversion, stability, and cost reduction in pharmaceutical manufacturing.
Patent CN104774889B details a novel fructosyltransferase method for sucrose-6-acetate, offering high yield and purity for reliable supply chain integration.
Patent CN118063351B reveals immobilized enzyme process for high-purity chiral beta-amino acids, offering cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN102517361A details lipase-catalyzed arbutin synthesis offering mild conditions and high purity for reliable cosmetic ingredient supply chains.
Patent CN115851694A details a novel immobilized enzyme method for synthesizing 2'-fluoro-deoxyribonucleosides, offering superior stability, reusability, and cost-effective manufacturing for antiviral intermediates.
Patent CN107858384A reveals a fusion enzyme method for L-tert-leucine. Offers high purity, thermal stability, and reusable biocatalysts for cost-effective pharmaceutical intermediate manufacturing.
Patent CN105368913A reveals dual-enzyme immobilization for chiral amino acids. Offers high purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN105368913A reveals dual-enzyme immobilization for high-purity chiral unnatural amino acid production with significant cost and supply chain advantages.
Patent CN107099516A details high-efficiency enzymatic UDCA production. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN106191150A details a co-immobilized enzymatic method for D-alanine. Achieves >98% purity with continuous 55-day operation, offering significant supply chain stability and cost reduction.
Patent CN113061594A reveals novel immobilized transaminase mutants for sitagliptin synthesis, offering superior stability in aqueous isopropanol and reduced manufacturing costs.
Patent CN113061594A details a robust immobilized transaminase process for sitagliptin intermediates, offering superior stability and simplified solvent systems for cost-effective API manufacturing.
Patent CN114317472B details a novel biocatalytic route for (S)-nornicotine using immobilized imine reductase, offering superior purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN114045271B reveals high-efficiency biocatalysis for Atazanavir intermediates. Discover cost reduction and supply chain reliability with immobilized enzyme technology.
Discover the advanced enzymatic method for producing high-purity fluvastatin diol. This patent-based insight highlights cost reduction and superior chiral selectivity for pharmaceutical manufacturing.
Patent CN116103254B reveals stable enzyme mutants for UDCA. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.